Group 1 - The company Shandong Pharmaceutical Glass (600529) plans to issue shares at a price of 16.25 yuan per share to raise a total of 3.235 billion yuan, which will be used to supplement working capital after deducting issuance costs [1] - After the issuance, China National Pharmaceutical Group Corporation will become the controlling shareholder of Shandong Pharmaceutical Glass, changing the actual controller to the State-owned Assets Supervision and Administration Commission of the State Council [1] - The company aims to leverage the resources of China National Pharmaceutical Group in areas such as pharmaceutical research and development, industrial manufacturing, and global network layout to support its transformation into a technology-driven international enterprise [1] Group 2 - The raised funds will enhance the company's research and innovation capabilities and increase investment in new technologies and products, aiming to create core competitive products in various pharmaceutical packaging material segments [2] - Shandong Pharmaceutical Glass, established in 1970 and listed in June 2002, is a leading enterprise in the pharmaceutical glass industry, mastering core technologies for borosilicate molded bottle manufacturing [2] - The company produces over 200 types of products across six major series, including molded pharmaceutical glass bottles and infusion bottles, with a domestic market share exceeding 85% for its molded bottle products [2]

Core Insights - The revised Drug Administration Law in China mandates that the State Council's drug supervision department reviews chemical raw materials, excipients, and packaging materials together with drug approvals, ensuring comprehensive quality standards and production processes are evaluated [1] Group 1: Review Process - The new law specifies that the approval process for drugs will include a joint review of raw materials, excipients, and packaging materials [1] - The registration platform will now indicate two types of review results: "A" for approved materials and "I" for those not yet approved [1] Group 2: Review Results Distribution - As of 2025, the distribution of review results for Chinese borosilicate glass packaging shows that "A" class results total 239, accounting for 47%, while "I" class results account for 53% [2] - In the "A" class results, there are 164 domestic products and 75 imported products, while the "I" class results include 203 domestic and 65 imported products [4] Group 3: Product Categories - The "A" class results for injection bottles show a significant number, with 116 for injection bottles, 77 for ampoules, 3 for infusion bottles, and 43 for others [4] - Conversely, the "I" class results for injection bottles are also substantial, with 164 for injection bottles, 85 for ampoules, 14 for infusion bottles, and 5 for others [7]